Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US
Recruiting
Observational Study
Obstructive Hypertrophic Cardiomyopathy (oHCM)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 362 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to understand the real-world clinical outcomes and treatment patterns of adults with obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten, and to understand patient and physician experiences with mavacamten treatment, in the US community-based practice
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Phase I: retrospective chart review
For inclusion in the study, participants must meet ALL of the following criteria:
* Are an adult aged 18 or over at baseline
* Have a confirmed diagnosis of obstructive hypertrophic cardiomyopathy (HCM)
* Have been prescribed mavacamten for …
Contacts
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
855-907-3286
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT